GNFTF - Expected Value Investing: Analyzing Genfit's Huge Potential
In this article, I'd like to continue my recent focus on some of the major players in the NASH drug development race. Genfit (OTCPK: GNFTF), a France-based biotech, is one of the firms farthest along in the development process - it is currently in process of conducting a Phase 3 trial to evaluate its lead drug candidate elafibranor's ability to achieve NASH resolution, and expects a pivotal data readout sometime in 2019. If this readout provides positive data, Genfit will be well positioned to capture a significant portion of the multi-billion dollar NASH fibrosis